File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis b

TitleNucleoside/nucleotide analogues in the treatment of chronic hepatitis b
Authors
KeywordsEfficacy
Hepatitis B virus
Oral therapy
Resistance
Issue Date2011
PublisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/
Citation
Journal of Antimicrobial Chemotherapy, 2011, v. 66 n. 12, p. 2715-2725 How to Cite?
AbstractThe current available agents for the treatment of chronic hepatitis B (CHB) include immunomodulatory agents, such as interferon-α and pegylated interferon-α, and oral nucleoside/nucleotide analogues (NAs), including lamivudine, adefovir, telbivudine, entecavir and tenofovir. The NAs work mainly by inhibiting hepatitis B virus (HBV) DNA polymerase activity and thus suppress HBV replication. Oral NAs have become the mainstay of CHB treatment, mainly due to their profound viral suppressive effects and also due in part to the ease of single daily dosing and lack of significant side effects. One major drawback of NA therapy is the development of drug resistance mutations with long-term treatment. Lamivudine, the first oral NA approved for CHB patients, is associated with high rates of drug resistance, with resultant virological relapse and biochemical flare. Fortunately, newer and more potent NAs, such as entecavir and tenofovir, have very low resistance rates, with potent and durable viral suppression. This review is aimed at the current developments in NAs for CHB treatment, detailing the mechanisms of antiviral activity of the different agents, the efficacy of viral suppression, the achievement of treatment endpoints, the development of drug resistance and the optimal strategies for using these drugs. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163419
ISSN
2015 Impact Factor: 4.919
2015 SCImago Journal Rankings: 2.157
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2012-09-05T05:31:09Z-
dc.date.available2012-09-05T05:31:09Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal of Antimicrobial Chemotherapy, 2011, v. 66 n. 12, p. 2715-2725en_HK
dc.identifier.issn0305-7453en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163419-
dc.description.abstractThe current available agents for the treatment of chronic hepatitis B (CHB) include immunomodulatory agents, such as interferon-α and pegylated interferon-α, and oral nucleoside/nucleotide analogues (NAs), including lamivudine, adefovir, telbivudine, entecavir and tenofovir. The NAs work mainly by inhibiting hepatitis B virus (HBV) DNA polymerase activity and thus suppress HBV replication. Oral NAs have become the mainstay of CHB treatment, mainly due to their profound viral suppressive effects and also due in part to the ease of single daily dosing and lack of significant side effects. One major drawback of NA therapy is the development of drug resistance mutations with long-term treatment. Lamivudine, the first oral NA approved for CHB patients, is associated with high rates of drug resistance, with resultant virological relapse and biochemical flare. Fortunately, newer and more potent NAs, such as entecavir and tenofovir, have very low resistance rates, with potent and durable viral suppression. This review is aimed at the current developments in NAs for CHB treatment, detailing the mechanisms of antiviral activity of the different agents, the efficacy of viral suppression, the achievement of treatment endpoints, the development of drug resistance and the optimal strategies for using these drugs. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/en_HK
dc.relation.ispartofJournal of Antimicrobial Chemotherapyen_HK
dc.subjectEfficacyen_HK
dc.subjectHepatitis B virusen_HK
dc.subjectOral therapyen_HK
dc.subjectResistanceen_HK
dc.titleNucleoside/nucleotide analogues in the treatment of chronic hepatitis ben_HK
dc.typeArticleen_HK
dc.identifier.emailFung, J: jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1093/jac/dkr388en_HK
dc.identifier.pmid21965435-
dc.identifier.scopuseid_2-s2.0-81855168414en_HK
dc.identifier.hkuros208912-
dc.identifier.hkuros210702-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81855168414&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume66en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2715en_HK
dc.identifier.epage2725en_HK
dc.identifier.isiWOS:000297244100004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats